

NOT FOR PUBLICATION  
FOR OFFICIAL USE ONLY

POLIOMYELITIS SURVEILLANCE  
REPORT NO. 32 JULY 8, 1955

Department of Health Education and Welfare  
Public Health Service                                  Communicable Disease Center

Poliomyelitis Surveillance Unit  
50 Seventh Street, N. E.  
Atlanta, Georgia

---

SPECIAL NOTE

The information in this report represents a factual summary of data reported to the Poliomyelitis Surveillance Unit from State Health Departments, Epidemic Intelligence Service Officers, participating laboratories, and other pertinent sources. Much of the material is preliminary in nature and is subject to change. The distribution of this report is strictly limited to federal and state officials, to directors of participating laboratories and to other official or non-official persons having responsibility for the control of poliomyelitis in the nation. It is understood that this report will not be quoted in public nor will its contents be released to the press or to unauthorized persons. Any release of this information will be made by the Office of the Surgeon General, U. S. Public Health Service. State Health Officers, of course, are free to reveal any information they may wish concerning data from their state.

All readers should be cautioned regarding the limitations of the data presented herein. Current and cumulative data are given concerning reported cases of poliomyelitis in vaccinated persons and among their familial and community contacts. It should be recognized that these data do not constitute a controlled evaluation of poliomyelitis vaccine. For this reason, interpretations and conclusions based on material in these reports must be guarded.

---

Table of Contents

- I. Current Poliomyelitis Morbidity Trends
- II. Plans for Reorientation of the Surveillance Program
- III. Routine Poliomyelitis Surveillance
- IV. Polio-Like Diseases

## I. Current Poliomyelitis Morbidity Trends

Poliomyelitis incidence by week for the current poliomyelitis season, with similar data for the three preceding years, is presented in the accompanying figure, drawn from data published by the National Office of Vital Statistics. For the past three weeks of the current year, national incidence has remained relatively stable as opposed to sharp increases recorded for the corresponding period during 1952, 1953, and 1954.

This year's poliomyelitis incidence by states for the weeks ending May 28 through July 2 is presented in Table 1 together with a six week total for this and the past three years. Few states have shown any marked rise for the past two weeks. Incidence in the Middle Atlantic and Northwestern states remains high compared to the past three years' experience whereas incidence in the West South Central States remains low.

## II. Plans for Reorientation of the Surveillance Program

The National Poliomyelitis Surveillance Program was announced on April 28, 1955 and inaugurated on May 1st with PSU Report No. 1. For more than a year discussions had taken place within the Communicable Disease Center and with State Epidemiologists and others concerned over the desirability of developing such a program. The occurrence of the Cutter incident led to an acceleration of these plans. The response from the State Health Departments and from the participating laboratories has been prompt and thorough. A two-way flow of information through the PSU reporting mechanism has been established so that all responsible and authorized persons have been kept currently informed as to the status of the changing situation.

Now the Cutter incident is apparently over. The immediate epidemiologic emergency seems to have passed. It is time for a careful reappraisal of the objectives of the National Poliomyelitis Surveillance Program. Future procedures both for field epidemiology and for laboratory confirmation should be planned in relation to future needs and anticipated problems. The experience of the past two months dictates a number of changes. The routine aspects of surveillance procedures should be cut back to a basic minimum. The short supply of vaccine to date with the probable limitation of its use for some time in the future to children in the NFIP supported program, or to 5 to 9 year olds, provides a unique opportunity to undertake broad scale studies of the effectiveness of the vaccine.

Detailed plans and proposals are now in the process of preparation and should be forwarded to each State Health Officer and participating laboratory in the near future. Several states have already developed plans for special studies designed to utilize existing situations in their areas. The populations that were included in the 1954 Vaccine Evaluation Program will be most interesting to study again this year.

The services of the Communicable Disease Center will be made available to the States to the maximum possible degree in support of maintaining a continuing Routine National Poliomyelitis Surveillance, and to assist in special studies designed to evaluate the effectiveness of polio vaccine. A study of any epidemics of polio that may occur this year will be most important. Epidemic Intelligence Service Officers will be available on call for such epidemic investigations, and priority in assignments of EIS officers to states will be made in relation to special studies of polio vaccine that are undertaken.

### III. Routine Poliomyelitis Surveillance

Table 2 summarizes poliomyelitis cases in vaccinated individuals, in parents and siblings of vaccinated individuals, and in community contacts accepted by PSU through July 6, 1955. (See Tabular Summary for details of the cases accepted since June 23 and revisions of previously listed cases.)

Table 3 presents a tabulation of these cases by interval between inoculation and onset of symptoms. Cases in which the vaccinated individual received two inoculations are listed according to the interval following the second inoculation and according to the manufacturer of the vaccine used for the second inoculation.

Table 4 presents a comparison of "reported" and "expected" cases for the weeks ending April 23 through July 9 among children inoculated in NFIP clinics through May 7. Reported cases are now subdivided according to paralytic status; sufficient data are not available for a similar treatment of the "expected" numbers of cases.

The calculations of "expected" cases are based on five-year medians of weekly incidence for that group of states receiving vaccine from a particular manufacturer, compiled from reports to NOVS by the States. Weekly incidence figures are adjusted to correspond to week of onset. Information on the numbers of eligibles and amounts of vaccine given as first inoculations was provided to PSU by the NFIP. It is further assumed that 10% of polio cases occur in children in the first and second grades. The "expected" numbers are based on past years' reported incidence and thus represent a rough estimate of the number of cases that would have occurred in this number of first and second grade children if they had not been vaccinated.

It should be emphasized that this comparison is an effort to adjust for geographic differences and for the varying number of children inoculated with vaccine from the different manufacturers. The table does not adjust for current deviation from the 5-year average. This must be considered in any interpretation of Table 4.

Some data have now become available on first inoculations given since May 7. Approximately 1,200,000 doses of Parke-Davis vaccine were given as first inoculations between May 7 and June 18, almost half of this being in New York and the rest mainly distributed among Arizona, California, Connecticut, Massachusetts, Minnesota, New Hampshire, Oregon, Rhode Island, Utah, Vermont, Washington, and Wisconsin. No Pitman-Moore vaccine and only small amounts of Lilly and Wyeth Vaccines were used for first inoculations during this period.

"Expected" numbers of cases among children who received first inoculations of Parke-Davis vaccine during this period have been computed in much the same manner as for Table 4. It is assumed that most of the inoculations were given between May 14 and June 14, approximately equal numbers being given in each of these three weeks. On this basis, the "expected" number of cases among children having first inoculations of Parke-Davis vaccine between May 8 and June 18 and having onsets between May 8 and July 2 is about 21 whereas the number of PSU accepted cases in such children is 17 (8 paralytic and 9 non-paralytic). Ten of these cases are from New York (5 paralytic and 5 non-paralytic).

Four cases in children having first inoculations with Lilly vaccine since May 7 have been accepted by PSU (one paralytic and three non-paralytic) and none in children inoculated with Wyeth vaccine. There are not sufficient data available to warrant the computation of expected numbers for this period for these manufacturers.

Several recent virus isolations in all categories are reported as revisions in the Tabular Summary.

A case is listed in this report for the first time from Puerto Rico. Vaccine from two lots produced by Parke-Davis was used in private practice by physicians in Puerto Rico, no government or NFIP sponsored program having been initiated there as yet.

Previous PSU Summaries have described the occurrence of minor illnesses among Cutter vaccinated children one to two weeks after inoculation. Dr. Richard White, Epidemic Intelligence Service Officer, now reports another case of this type from Texas:

"An 18 month old white female residing in Houston received one shot of Cutter vaccine, lot No. E6045, from her private physician on April 18. On April 24 this patient developed a sore throat and fever of 102° without neurological symptoms of any kind. She was given 2cc of combiotic and cleared up in one day. She had a past history of receiving 2cc of polio gamma globulin on April 2. From a stool specimen collected May 7, type I poliomyelitis virus has been isolated by Dr. Irons. This patient was never diagnosed as having poliomyelitis. I believe this fits in well with the cases of minor illness observed in Cutter vaccinates in other states. There was no illness among her parents and she has no siblings."

Further progress on studies utilizing the complement-fixation test are reported by Dr. Joseph Melnick, Yale University School of Medicine, in a letter dated June 17 to Dr. Carl Bernet, Epidemic Intelligence Service Officer in Colorado. Dr. Melnick has been running tests on a group of Colorado children who received Cutter vaccine, either 0.1 cc intradermally or 1.0 cc intramuscularly:



"Of the 173 sera from children inoculated intradermally:

- 1 showed a strong monotypic Type I response
- 2 showed strong Type III responses
- 9 gave weak positive responses (1 for Type I,  
4 for Type II, 4 for Type III)
- 12 had trace responses

Of the 13 sera from children inoculated intramuscularly:

- 3 gave strong Type I responses indicative of  
current or recent infection (2 of these were  
monotypic for Type I; 1 was ditypic, for Types I  
and II)."

#### IV. Polio-Like Diseases

PSU receives occasional reports on "polio-like" diseases, such as encephalitis and Coxsackie infections. These reports are of interest in relation to the incidence of poliomyelitis in the same areas, and will, from time to time, be briefly summarized.

The California State Department of Public Health is conducting a surveillance program on encephalitis as in previous years. In its report of June 21, a total of 152 cases of acute encephalitis have been reported in the state from January 1 to June 18, 1955, as compared with 212 cases during the same period for 1954. No laboratory-proven cases of arthropod-borne encephalitis have been reported in the state this year. Of the 152 reported cases, etiology was undetermined in 48 while 104 occurred as sequelae of the following viral infections: measles-49, mumps-46, chicken pox-7, and others-2. As part of the routine encephalitis surveillance program in California, 43 mosquito pools have been tested, but to date no virus isolations from these pools have been reported.

The recent occurrence of Eastern Equine Encephalitis in Louisiana is noted in the following letter from Dr. M. Schaeffer, CDC Virus and Rickettsial Laboratory, Montgomery, to Regional Medical Director, USPHS, dated June 30, 1955:

On June 17, 1955, the brain of a horse dying of febrile illness with neurologic symptoms was received in Montgomery from Dr. H. B. Elliott of the State Livestock Sanitary Board of Louisiana. By June 21, Dr. R. E. Kissling, of our Veterinary Research Unit, was able to report to Dr. Elliott the isolation and identification of eastern equine encephalitis virus. On the same day a blood specimen was received from a child in comma at a Baton Rouge hospital. A second possible case of encephalitis is also suspected in this area.

Thus far at least 19 equine cases of encephalitis (including the one confirmed above) have occurred near Brittany, Louisiana, in the center of Ascension Parish. No cases have been recognized as yet in surrounding areas."

(This Summary Report was prepared by Dr. Neal Nathanson, Dr. Wm. Jackson Hall, and Dr. Alexander D. Langmuir, with assistance from the Statistics Section, CDC.)



# CURRENT U.S. POLIO INCIDENCE COMPARED WITH YEARS 1952-1954

DATA PROVIDED BY NATIONAL OFFICE OF VITAL STATISTICS

NUMBER OF REPORTED CASES








Table 1

## TREND OF 1955 POLIOMYELITIS INCIDENCE

STATE	Cases Reported to NOVS*						6 Week Total	Comparable Totals in:		
	5/28	6/4	6/11	6/18	6/25	7/2		1954	1953	1952
United States	240	251	300	266	277	331	1665	2261	2319	1782
North East										
Maine	-	1	-	1	1	-	3	2	8	5
New Hampshire	-	-	-	-	-	-	-	2	9	2
Vermont	-	-	1	-	1	-	2	1	1	1
Massachusetts	-	-	1	2	4	1	8	10	18	6
Rhode Island	-	-	-	-	1	-	1	1	3	-
Connecticut	-	-	-	-	-	5	5	21	21	3
New York	18	11	21	19	16	25	110	56	132	52
New Jersey	2	5	6	2	4	5	24	15	15	7
Pennsylvania	3	9	7	8	10	10	47	21	26	9
North Central										
Ohio	6	9	20	4	12	22	73	63	83	56
Indiana	1	2	2	3	4	4	16	23	35	20
Illinois	9	5	8	9	13	10	54	39	64	27
Michigan	4	3	11	9	9	9	45	88	60	24
Wisconsin	5	5	7	3	4	9	33	23	16	22
Minnesota	3	5	2	3	6	2	21	20	73	13
Iowa	6	2	4	4	3	10	29	40	40	47
Missouri	1	4	3	3	-	4	15	21	60	16
North Dakota	-	1	1	1	1	3	7	6	4	4
South Dakota	6	2	-	3	1	-	12	4	7	4
Nebraska	3	1	2	-	1	3	10	39	28	11
Kansas	3	2	-	5	8	2	20	33	41	29
South										
Delaware	5	3	2	1	-	1	12	2	3	2
Maryland	7	3	5	4	2	3	24	3	12	1
District of Col.	2	-	1	-	1	1	5	1	6	2
Virginia	4	2	3	4	6	8	27	22	34	8
W. Virginia	2	1	3	-	1	3	10	14	22	21
North Carolina	4	-	6	1	3	8	22	28	109	25
South Carolina	1	1	5	1	8	6	22	40	17	5
Georgia	3	5	5	1	4	5	23	89	76	38
Florida	6	15	9	29	14	10	83	179	60	63
Kentucky	6	9	6	-	5	3	29	23	37	13
Tennessee	3	4	3	4	3	3	20	26	59	21
Alabama	3	9	4	9	3	8	36	53	141	23
Mississippi	4	8	9	5	7	9	42	72	81	89
Arkansas	2	6	3	7	1	5	24	50	45	24
Louisiana	11	6	10	14	12	17	70	95	93	102
Oklahoma	1	-	3	5	3	4	16	64	96	39
Texas	37	52	52	62	45	43	291	469	358	615

Table 1 (continued)

STATE	Cases Reported to NOVS*						6 Week Total	Comparable Totals in:		
	During Week Ending: 5/28	6/4	6/11	6/18	6/25	7/2		1954	1953	1952
West										
Montana	1	-	-	-	2	no report	3	3	3	13
Idaho	22	4	11	3	7	8	55	3	3	7
Wyoming	-	-	-	-	1	1	2	17	5	4
Colorado	5	5	2	3	3	6	24	26	23	14
New Mexico	-	1	1	-	3	10	15	10	10	10
Arizona	1	3	1	1	1	6	13	26	20	23
Utah	1	-	1	1	2	2	7	11	9	1
Nevada	-	2	7	5	3	6	23	9	-	2
Washington	5	2	9	2	2	3	23	16	11	45
Oregon	6	4	4	4	3	3	24	18	13	10
California	28	39	39	21	33	25	185	364	229	204

\*National Office of Vital Statistics

Table 2

Poliomyelitis Cases with Some Association  
With Poliomyelitis Vaccine  
(PSU Accepted Cases through July 7, 1955)

	C		L		FD		PM		W		*	
	P	NP	P	NP	P	NP	P	NP	P	NP	P	NP
<u>Cases Vaccinated 5/7 or before with onsets less than 31 Days after vaccination</u>												
Revised Totals 6-22	60	11	16	22	2	2	3	2	9	3		
	71		38		4		5		12			
New Cases 6-22 thru 7-6	2	1	0	1	0	0	0	0	0	0		
	3		1		0		0		0			
Total thru 7-6	62	12	16	23	2	2	3	2	9	3	0	0
	74		39		4		5		12		0	0
<u>Cases Vaccinated 5/7 or before with onsets 31 or more Days after vaccination</u>												
Revised Totals 6-22	1	1	3	10	1	3	2	0	1	0		
	2		13		4		2		1			
New Cases 6-22 thru 7-6	0	0	5	5	1	0	0	0	0	0		
	0		10		1		0		0			
Total thru 7-6	1	1	8	15	2	3	2	0	1	0	0	0
	2		23		5		2		1		0	0
<u>Cases Vaccinated 5/8 or later with Onsets Less than 31 days after vaccination</u>												
Revised Totals 6-22			1	1	5	7	0	0				
			2		12		0					
New Cases 6-22 thru 7-6			0	3	4	2	1	0				
			3		6		1					
Total thru 7-6	0	0	1	4	9	9	1	0	0	0	0	0
	0		5		18		1		0		0	0
<u>Cases in Family Contacts of Vaccinated Individuals</u>												
Revised Totals 6-22	49	14	18	5	13	9	2	0	10	3	2	0
	63		23		22		2		13		2	
New Cases 6-22 thru 7-6	16	6	4	1	6	2	0	0	0	0	3	2
	22		5		8		0		0		5	
Total thru 7-6	65	20	22	6	19	11	2	0	10	3	5	2
	85		28		30		2		13		7	

Table 2 (Continued)

	C		L		FD		PM		W		*	
	P	NP	P	NP	P	NP	P	NP	P	NP	P	NP
Cases in Community Contacts of Vaccinated Individuals												
Revised	11	2	5	0	1	0	0	1	4	3		
Totals 6-22	16		5		1		1		7			
New Cases	2	0	0	0	1	0	0	0	0	0		
6-22 thru 7-6	2		0		1		0		0			
Totals thru	16	2	5	0	2	0	0	1	4	3	0	0
7-6	18		5		2		1		7		0	

\*Two inoculations with vaccines of two manufacturers.







Table 4

Comparison of Expected\* and Reported\*\* Cases of Poliomyelitis  
Among Children Inoculated in NFIP Clinics from April 15 to May 7, 1955

(PSU Accepted Cases through July 6, 1955)

Vaccine Mfr.*** and Number Vaccinated		Cases	Apr. 23	Apr. 30	May 7	May 14	May 21	May 28	June 4	June 11	June 18	June 25	July 2	July 9
Cutter 309,000	Reported	P	7	14	8	1	2							
		NP	1		5	2				1	1			
	Total	8	14	13	3	2	-	-	1	1	-	-	-	
	Expected Total	1	1	1	1	2	1	1	1	2	3	2	3	4
Lilly 2,514,000	Reported	P	3	2	3	2	4	3	1	2	2	1		
		NP	1	3	4	8	7	10	1	1	3		1	
	Total	4	5	7	10	11	13	2	3	5	1	1	-	
	Expected Total	3	4	4	6	6	7	11	15	20	22	28	38	
Parke-Davis 834,000	Reported	P					1	1	1		1			
		NP						3	1	1				
	Total	-	-	-	-	1	4	2	1	1	-	-	-	
	Expected Total	0-1	0-1	0-1	0-1	1	1	1	1	1	2	4	4	10
Pitman-Moore 411,000	Reported	P			1	1			3					
		NP				1	1							
	Total	-	-	1	2	1	-	3	-	-	-	-	-	
	Expected Total	0-1	0-1	0-1	0-1	0-1	0-1	0-1	1	1	1	2	3	5
Wyeth 776,000	Reported	P		1	2	2	3	1	1					
		NP				2	1							
	Total	-	1	2	4	4	1	1	-	-	-	-	-	
	Expected Total	0-1	0-1	0-1	0-1	0-1	0-1	0-1	0-1	0-1	1	2	3	3

Footnotes on Back

\*Expected Cases estimated from weekly 5-year medians of cases of poliomyelitis (paralytic and non-paralytic) reported to National Office of Vital Statistics by the States.

\*\*Reported Cases include only cases accepted by PSU and vaccinated in NFIP Clinics April 16 through May 7, 1955.

\*\*\*CUTTER vaccine was used in Idaho, Nevada, Arizona, New Mexico, and southern California. LILLY vaccine was used in Texas, Oklahoma, Louisiana, Arkansas, Mississippi, Alabama, Tennessee, Florida, Georgia, South Carolina, North Carolina, Virginia, West Virginia, Indiana, and parts of Ohio, California and Colorado. PARKE-DAVIS vaccine was used in Michigan, Illinois, Iowa, Wyoming, Utah, and part of Colorado. PITMAN-MOORE vaccine was used in Kentucky, Missouri, Kansas, and Nebraska. WYETH vaccine was used in Pennsylvania, Delaware, Maryland, District of Columbia, and part of Ohio.



POLIOMYELITIS AMONG VACCINATED INDIVIDUALS  
(PSU Accepted Cases June 23-July 6, 1955)

PSU CASE NO	Residence	Ini- tials	Age	Sex	Date Inoc	Date	Date	Site Inoc	Site Para	Mfr	Lot No.	Remarks
						1st Symp	1st Para					
NM-1	Albuquerque	CG	7	F	4-29	6-16	<sup>NEW</sup> None	IA	None	C	?6037, ?6038 ?6039, ?5976	Spinal fluid, 198 cells non-paralytic
Ark-3	Ft. Smith	JAM	8	F	4-19	5-11	None	IA	None	L	5026-649347	Spinal fluid 400 cells non-paralytic
Tex-22	Corpus- Christi	TB	6	M	4-20	6-15	None	IA	None	L	7078-649343	Spinal fluid 443 cells
Tex-23	Houston	DC	6	M	4-19	6-9	None	IA	None	L	7078-649343	Spinal fluid 119 cells
Tex-24	Robstown	EA	8	M	4-20	6-12	None	IA	None	I	7078-649343	Spinal fluid 75 cells
Minn-1	Buffalo Village	PO	6	F	5-27	6-19	None	?	Ncnc	PD	029126A	Spinal fluid 3 cells
Utah-1	Hiawatha	MO	7	M	4-27	6-18	6-20	IA	Bulbar	PD	028860B	
Tenn-6	Memphis	CG	8	F	4-27	6-13	6-14	RA	Legs	L	7079-649341	
Tenn-7	Memphis	JJ	8	M	5-27	6-19	None	RA	None	L	7078-649341	Spinal fluid 549 cells
NY-10	Brooklyn	MC	7	F	6-2	6-21	6-24	IA	Face	PD	029129A	Bulbar
NY-11	Liberty	MF	8	M	4-19	6-18	6-23	?	bulbar	L	?	Vaccinated in Texas
NY-12	Oceanside	BS	8	M	5-26	6-23	6-24	IA	IA	PD	028850B 029129A	
Va-7	Alexandria	DP	8	F	4-27	6-16	None	?	None	L	8122-649334	Spinal fluid, 104 cells non-paralytic
Va-8	Pulaski	RS	7	M	4-28	7-2	None	?	None	L	7078-649343	Spinal fluid, 200 cells non-paralytic
Cal-37	L.A.Co.	RVanV	6	M	4-22	5-3	5-6	IA	RL	C	E5976	
Cal-38	L.A.Co.	CR	7	M	4-22	5-11	None	IA	None	C	?E5970 ?E5976	

VACCINATED CASES (CONTINUED)

PSU CASE NO	Residence	Ini- tials	Age	Sex	Date Inoc	Date 1st Symp	Date 1st Para	Site Inoc	Site 1st Para	Lot MFr No.	Remarks
Cal-39	L.A.City	SB	7	M	5-18	5-21	5-26	RA	LL	PD 028848A	Spinal Paralytic
Cal-40	L.A.City	SH	6	F	5-16	5-19	None	?	None	PD 028848A	
Cal-41	Contra Costa Co.	LM	7	M	5-20	5-25	None	IA	None	L 8124-649336	
Cal-42	Contra Costa Co.	RS	36	F	<u>4-13</u> 5-29	5-30	6-7	IA	RA,RL	C E6045 PM 175E011	Spinal paralytic
Ala-2	Snowdown	KW	7	F	4-20	5-7	?	?	LL	L 5079-649338	
Miss-4	Leakesville	GH	7	F	4-18	5-25	5-28	IA	LL	L 5080-649339	
Wis-2	Madison	LS	8	M	6-22	6-26	6-27	IA	bulbar	PD 029127A	
NC-1	Mocksville	SBH	8	F	4-21	6-20	6-27	7RA	LL	L 5080- 649339	RA also paralyzed. Sister developed back weakness 6-27.
NC-2	Lexington	RGL	8	M	4-26	6-8	6-11	?RA	RL	L 5080-649339	

REVISIONS

Revised Items Underlined

Miss-2	Carthage				-----Dropped---not polio-----						
Ill-2					Dropped--final diagnosis "not polio"						
Wis-1	Kaukauna	DK	8	M	<u>5-18</u>	6-17	None	IA	None	PD 029127A	<u>Spinal fluid 400 cells</u>
Tex-7	SanAngelo	DK	7	M	<u>4-21</u>	5-4	None	IA	None	L 7078- 649343	<u>Type 3 (6-24) Irons</u>
NY-3	Niagara Falls	LS	8	F	<u>5-24</u>	5-26	None	IA	None	PD 029129C	
Ga-2	Smyrna	SS	2	M	<u>4-20</u>	4-29	5-2	IA	IA	C ?E6044 ?E5973	<u>Type 1 isolated (6-29)</u> <u>Montgomery</u>
Md-2	Hyattsville	MW	6	F	4-26	5-25	6-1	?	Legs	W 236	<u>Type 1 isolated</u> <u>(6-29) NIH</u>
Ida-18	Grace	KA	7	F	4-19	5-21	?	IA	trunk	C E6039 E6058	<u>Type 1 isolated</u> <u>(6-29) RML</u>
Cal-16	Vallejo	EG	36	F	4-21	4-27	4-30	IA	IA	C E6045	<u>Deleted as not polio. Now</u> <u>accepted following isolate</u> <u>ion Type 1 Lannette 6-24</u>

Vaccinated Cases (CONTINUED)

PSU	Residence	Ini- tials	Age	Sex	Date Inoc	Date 1st Symp	Date 1st Para	Site Inoc	Site Para	Lot Mfr. No.	Remarks
Revisions (continued)											
Pa-4	Bucks Co.	PE	7	F	5-2	5-7	5-13	IA	LA	W 23614	Died 5-25 <u>Type 1 (Henle)</u> <u>(7-5)</u>
Pa-6	Harrisburg	DM	6	M	4-28	5-14	None	IA	None	W 23612	<u>Type 2 Henle (7-5)</u>
Nev-4	Sparks	TM	2	M	4-22	4-24	None	IA	None	C 85974	<u>Type 1 Lennette (7-1)</u>
Mass-1	Boston	AM	6	M	5-23	6-16	6-16	IA	<u>LL</u>	PD 028849A	<u>IA also paralyzed.</u>





POLIOMYELITIS AMONG UNVACCINATED PERSONS GIVING HISTORY OF FAMILIAL CONTACT WITH INDIVIDUALS  
WHO HAVE RECEIVED POLIOMYELITIS VACCINE  
(PSU Accepted Cases June 23-July 6, 1955)

Vaccinated Individuals

Poliomyelitis Case (Not Vaccinated)

PSU CASE NO	Residence	Ini- tials	Age	Sex	Date Inoc	Date Illness	Type Illness	Lot Mfr No.	Ini- tials	Age	Sex	Date 1st Symp	Date 1st Para	Site 1st Para	Remarks
NM-X4	Las Cruces	OH	9	F	4-21	None	None	C E6037	BH	3	F	6-17	6-18	RL	Quadriplegia.
NY-X8	Hastings	?G	?	?	5-20	None	None	PD 029128C	SG	6	F	6-17	?	Legs	
KY-X1	Louisville	JWM	8	F	4-28	None	None	PM ?	JPM	6	F	5-17	5-20	LA	
KY-X2	Louisville	JN	7	M	4-28	None	None	PM 175-C028	JLN	7mo.	M	6-5	6-7	L facial	Sister had slight fever since 6-9.
Ala-X8	Waverly	JLD	6	M	4-19	None	None	L 5079-64-9338	SFD	3	F	6-19	?	Bulbar	Died 6-20.
		MD	7	M	"	"	"	"	"	"	"	"	"	"	"
Ala-X9	Montgomery	GW	7	F	4-22	None	None	L 5079-64-9338	GW	6	M	6-15	6-18	LL	
		WW	9	M	6-21	"	"	"	"	"	"	"	"	"	"
Miss-X4	Greenville	CH	9	M	4-20	?	?	L 5080-649339	CH	2	M	6-1	6-7	LL	
		AH	7	F	4-20	?	?	L 5080-649339							
Utah-X1	Orem	?Y	?	F	4-20	?	?	PD 028860B	NY	?	M	5-28	?	?	Adult
		?Y	?	M	4-25	?	?	PD "							
PR-X1	Cabo Rojo, Puerto Rico	NAN	6	M	4-29	None	None	PD 028-850 or 028-861	LR	6mo.	F	5-15	5-18	RL	
					5-6										
					5-27										
Va-X3	DeWitt	?N	?	F	4-20	?	?	L ?	TN	14	M	6-2	None	None	Spinal fluid 50 cells, non- paralytic
Va-X4	Hampton	?S	?	F	4-28	?	?	L ?	RS	8	M	6-22	?	RL	
Cal-X12	L.A. Co.	GM	7	F	5-16	?	?	PD 028848B	JM	2	M	5-25	?	RA	
Cal-X13	L.A. Co.	WH	8	M	4-21	?	?	C E6038	MH	30	F	5-21	?	Spinal	
Cal-X14	L.A. Co.	ES	7	M	5-16	?	?	PD 028848A	SS	9	F	5-28	None	None	
Cal-X15	San Diego Co.	EG	6	F	4-16	?	?	C ?	SG	9	F	5-30	6-5	Legs	
					5-14	?	?	PD 029126A							
Cal-X16	L.A. Co.	MG	6	M	5-16	?	?	PD 028848A	SG	9	F	6-6	6-8	RL	

FAMILIAL CONTACTS (CONTINUED)

VACCINATED INDIVIDUALS

POLIO CASES (NOT VACCINATED)

PSU CASE NO	Residence	Ini- tials	Age	Sex	Date Inoc	Date Illness	Type Illness	Lot Mfr No.	Ini- tials	Age	Sex	Date 1st Symp	Date 1st Para	Site 1st Para	Remarks
Cal-X17	L.A. Co.	BM	7	M	4-18	?	Illness	C E6038	LM	2	F	5-1	None	None	
		SM	6	M	"	?	?	" "							
Cal-X18	L.A. Co.	MMcK	8	F	4-21	None	None	C E5976	MMcK	47	F	5-5	?	?	Spinal paralytic
Cal-X19	Stanislaus Co.	CS	2	F	4-18	4-25	polio	C E6045	FB	9mos.	F	5-9	None	None	Cousin
Cal-X20	San Diego Co.	LS	7	M	4-16	?	Illness	C ?	LS	1	M	5-8	5-9	RL	Spinal paralytic
Cal-X21	Orange Co.	MR	3	M	4-18	?	Illness	C ?	JR	25	M	5-2	?	?	Spinal paralytic
Cal-X22	San Diego Co.	MMcH	6	F	4-16	?	?	C ?	TMcH	8	F	5-12	5-14	LA,RL	Spinal paralytic
		JMcH	7	M	4-16	?	?	C ?							
Cal-X23	San Diego Co.	JVanV	8	M	4-16	?	?	C ?	SVanV	3	F	5-6	5-12	RL	Spinal paralytic
Cal-X24	L.A. Co.	KV	7	M	4-19	?	?	C E5970	LV	16	F	5-12	5-17	Bulbar	
Cal-X25	L.A. Co.	CM	6	M	4-18	?	?	C E5970	KM	9	F	5-11	5-17	Bulbo-spinal	
Cal-X26	L.A. Co.	EA	7	M	4-19	?	?	C E5976	RA	4	M	5-13	None	None	
Cal-X27	San Diego Co.	GC	7	M	4-16	?	?	C ?	BC	30	F	5-14	5-18	Legs	Spinal paralytic
Cal-X28	San Diego	RM	7	M	4-16	?	?	C ?	MM	14	M	5-18	5-19	RA	Spinal paralytic
Cal-X29	L.A. City	SB	6	M	4-19	?	?	C E6037	LB	3	M	5-19	5-21	LL	Spinal paralytic
Cal-X30	L.A. City	TS	3	M	4-16	?	?	C E5971	ES	34	F	5-18	5-21	RA	Spinal paralytic
Cal-X31	L.A. Co.	GB	7	M	4-20	?	Ill	C E5976	WB	9	M	5-17	None	None	
Cal-X32	L.A. Co.	ES	7	F	4-20	?	?	C E6038	DS	11	F	5-16	5-19	RA	Spinal paralytic
Cal-X33	Sonoma Co.	GE	2	M	4-20	?	Measles	C ?	TE	9mo.	M	5-16	5-19	Legs	Bulbar. All 3 had measles.
					4-27			PD ?							
		GE	3	M	4-20	?	Measles	C ?							
					4-27			PD ?							
Cal-X34	L.A. City	KC	6	M	5-18	?	?	PD 028848A	BC	30	F	5-21	None	None	
Cal-X35	Contra Costa Co.	SG	7	M	5-20	?	Ill	L ?	BG	31	F	5-27	None	None	
		LG	10	F	4-20	?	Ill	C E6045							
Cal-X36	Contra Costa Co.	LK	2	F	4-22	?	?	C E6045	BK	33	F	5-28	6-1	RA	Bulbo-spinal
		AK	10mo.	M	"	"	"	"							
Cal-X37	Contra Costa Co.	?W	?	?	4-22	?	?	C E6045	BW	31	F	5-16	None	None	
		?W	?	?	"	"	"	"							
Cal-X38	Contra Costa Co.	IE	6	F	4-26	?	Ill	L 8124-649336	RSE	3	F	5-19	None	None	

FAMILIAL CONTACTS (CONTINUED)

VACCINATED INDIVIDUALS

POLIO CASES (NOT VACCINATED)

PSU CASE NO	Residence	Ini- tials	Age	Sex	Date Inoc	Date Illness	Type Illness	Mfr	Lot No.	Ini- tials	Age	Sex	Date 1st Symp	Date 1st Para	Site 1st Para	Remarks
Cal-X39	San Diego Co.	MG	7	M	4-16	?	?	C	?	DG	2	M	5-28	5-31	Arms	Spinal paralytic
					5-14			PD	029126A							
Cal-X40	Santa Barbara Co.	LL	2	M	4-19	?	Cold	C	E5971	JL	36	M	5-21	None	None	Contacts had colds before and after inoculations.
		CL	5	F	4-19	?	Cold	C	E5971							
		JL	7	M	4-19	?	Cold	C	E6038 or E5928							
					?			L	8123-649339							
Cal-X41	Riverside Co.	?C	?	?	4-20	?	?	C	E5928	JC	36	F	5-28	None	None	
Ida-X27	Coeur d'Alene Co.	?McK	?	M	4-28	?	?	C	?E6038?E6044	?McK	29	F	6-27	6-29	?	Throat and arm paralysis.
Minn-X5	Kandi-Yohi Co.	?J	?	M	5-?	None	None	PD	129126A	DJ	1	?	6-24	6-26	LL	
Mass-X1	Braintree	LH	?	F	5-23	None	None	PD	?	SH	2	M	6-26	6-29	?	Quadriplegia
REVISIONS (Revised Items Underlined>)																
Va-X1	Arlington	Dropped: Autopsy revealed not polio.														
Va-X2	Alexandria City	TC	7	M	4-29	?	?	L	8122-649334	KC	1	F	5-31	?	Facial	Type 1 from case, vaccinated and unvaccinated contacts (6-29) NIH
		?C	8	M	4-29	?	?	"	"							
La-X1	New Orleans	JT	1	M	4-26	?	?	C	E5973	DT	33	M	5-18	?	Bulbar	Type 1 virus from patient and vaccinated contact 6-20(Dr. Potash)
Ore-X4	Dropped-vaccination sibling after onset of illness in case															
Ga-X2	Atlanta	AW	4	F	4-20	4-28	Tonsillitis	C	?E6044 ?E5973	JW	14	F	5-9	5-12	Trunk	Type 1 from AW, vaccinated contact (6-29) Montgomery
Ga-X3	Atlanta	GM	1	M	4-18	None	None	C	?E6044 ?E5973	PLM	38	M	5-3	5-13	RA	Type 1 virus from case 6-27 (Montgomery)
Md-X6	Lutherville	MT	6	F	4-25	None	None	W	23606	RT	10	F	5-14	?	LA,RA	Paralysis noted first 6-7. Type 1 virus from case (6-23) and contact (5-31), NIH.
Md-X7	Parkville	JM	7	F	?	5-26	Stomach ache	W	23606	JM	3	M	5-27	5-29	LL	Type 1 virus from case (6-20), from vaccinated contact (6-21), and from unvaccinated contacts (6-14), NIH.
Ida-X10	Lewiston	?A	7	F	4-19	?	?	C	?E6039 ?E6058	RA	3	M	5-14	5-18	RL	Type 1 virus from case 7-5 (RML).

FAMILIAL CONTACTS (CONTINUED)

VACCINATED INDIVIDUALS

POLIO CASES (NOT VACCINATED)

PSU CASE NO	Residence	Ini- tials	Age	Sex	Date Inoc	Date Illness	Type Illness	Lot Mfr No.	Ini- tials	Age	Sex	Date 1st Symp	Date 1st Para	Site 1st Para	Remarks
REVISIONS (Revised Items Underlined>)															
Ida-X11	Deary	?S	8	F	?	?	?	?E6039 ?E6058	SS	9	F	5-13	5-18	Trunk	<u>Type 1 virus from case 7-5 (RML).</u>
Ida-X12	Preston	?P	?	M	4-19	?	?	C E6039 E6058	NP	9	F	5-11	5-18	Legs	<u>Type 1 from case (6-29) RML and vaccinated contact.</u>
Ida-X13	Preston	"	"	"	"	"	"	"	JP	3	F	5-4	5-18	Legs	<u>Type 1 from vaccinated contact (6-29) RML.</u>
Ida-X17	Lewiston	?C	6	M	4-19	?	?	C ?E6039 ?E6058	RC	12	M	5-23	None	None	<u>CSF abnormal, non-paralytic. Type 1 virus from case and contact 7-5 (RML).</u>
Ida-X19	Bonnors Ferry	JH	7	M	4-27	None	None	C ?E6039 ?E6058	RH	13	M	5-18	5-22	RA	<u>Type 1 virus from case 7-5 (RML)</u>
Md-X9	Bowie	CP	7	F	?	6-3	Pharyngitis	W 236	VP	1	F	6-2	6-3	?	<u>Type 1 virus from case (6-29) NIH</u>
Ala-X8	Waverly	JLD	6	M	4-19	None	None	L 5079-64-9338	SFD	3	F	6-19	6-20	Bulbar	<u>Died 6-21.</u>
		MD	7	M	"	"	"	"	"	"	"	"	"	"	
Nev-X2	Carson City	WH	8	M	4-19	None	None	C E6039	FH	12	M	5-6	5-7	Legs	<u>Type 1 virus from case 7-1 (Dr. Lennette)</u>
Nev-X4	Gardnerville	CL	7	M	4-22	4-23	Fever Abdominal Pain	C E6039	BL	1	M	5-13	5-15	RL	<u>Paraplegis. Type 1 virus from case 7-1 (Dr. Lennette)</u>
Wash-X2	Vancouver	BR	2	F	4-15	None	None	C E5972	BR	33	F	5-9	None	None	<u>Spinal fluid 740 cells. Type 1 virus isolated from case, both vaccinated contacts, and two unvaccinated contacts 7-1 (Dr. Lennette.)</u>
		SR	1	F	4-15	4-19or20	Fever	C E5972							



POLIOMYELITIS AMONG UNVACCINATED PERSONS GIVING HISTORY OF COMMUNITY CONTACT WITH  
INDIVIDUALS WHO HAVE RECEIVED POLIOMYELITIS VACCINE  
(PSU Accepted Cases June 23-July 6, 1955)

Vaccinated Individuals

Polio Cases (Not Vaccinated)

PSU CASE NO	Residence	Ini- tials	Age	Sex	Date Inoc	Date Illness	Type Illness	Mfr	Lot No.	Ini- tials	Age	Sex	Date 1st Symp	Date 1st Para	Site 1st Para	Remarks
NEW																
Wash-C2	Seattle	BL	9	F	4-14	None	None	C	E5973	LB	7	F	5-8	5-12	Bulbar	
		NL	3	M	4-14	4-28	Fever	C	E5973							
Ida-C5	Orafino	?J	7	F	4-20	?	?	C	E6039 E6058	JF	4	M	6-17	?	Spinal	Playmates of WJ (Ida-X26) whose sister ?J was vaccinated.
Ill-C2	Chicago	?	6	M	5-4	None	None	PD	028863B or 028846B	RR	9	M	6-18	?	Bulbar	Cousin, visited one week.
REVISIONS (Revised Items Underlined)																
Ark-C1	Malvern	?	?	M	4-20	?	?	L	<u>7080-649342</u>	<u>LGG</u>	<u>1</u>	<u>F</u>	6-10	6-14	RL	Uncle
Ga-C1	Hepzibah	LT	?	?	4-18	None	None	L	<u>?5081-649340</u> <u>?7079-649341</u>	<u>DD</u>	<u>8</u>	<u>M</u>	5-12	5-20	LL	<u>Type 1 virus from unvaccinated contact (6-29) Montgomery</u>
Md-C4	Towson	AL	1	F	4-16	None	None	C	E6044	BC	1	M	5-22	5-29	LL	<u>Type 1 from case (6-29) NIH</u>
Md-C7	Silver Springs				classmates in school			W?		BR	7	F	5-24	?	RL	
Ida-C2	Jerome	VC	7	M	4-19	5-2	Paralytic Polio	C	E6039 E6058	JB	7	M	5-19	5-22	None	<u>Type 1 from Case RM (6-29) play- mate</u>
Ida-C1	Kellogg	3	7-yr-old neighbors-----					C	?E6039 ?E6058	CL	2	F	5-16	5-18	RL	<u>Paraplegia. Type 1 virus from case and mother 7-5 (RML).</u>
Miss-C2	Hattiesburg	TW	7	M	4-19	5-13	Headache	L	5080-649339	BW	11	M	5-31	6-4	Bulbar	
Miss-C1	Dropped same as Miss-C2															
Wash-C1	Seattle	<u>LW</u>	?	<u>F</u>	4-18	None	None	PD	028861 <u>B</u>	GG	3	F	<u>5-18</u>	<u>5-24</u>	<u>LL</u>	Playmate.
		<u>MW</u>	?	<u>F</u>	<u>4-29</u>	None	None	C	E5973							
		<u>SP</u>	?	<u>F</u>	"	"	"	"	"							

